---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-047974"
form_type: "8-K"
ticker: "BCLI"
cik: "0001137883"
company_name: "BRAINSTORM CELL THERAPEUTICS INC."
filed_at: "2024-04-17T23:59:59+00:00"
generated_at: "2026-06-03T21:31:28.518379+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# BrainStorm CEO Steps Down, CMO Promoted; Phase 3b Trial for NurOwn Planned

## Summary
- Co-CEO Stacy Lindborg resigns effective May 9, 2024, but will join the Board of Directors.
- Dr. Bob Dagher promoted from Chief Development Officer to Executive VP and Chief Medical Officer.
- Company plans registrational Phase 3b trial for NurOwn (ALS) under FDA Special Protocol Assessment.
- Separation agreement includes $300,000 lump sum payment and continued vesting of certain equity awards.

## SEC filing metadata
- accession: 0001104659-24-047974
- form_type: 8-K
- ticker: BCLI
- cik: 0001137883
- company_name: BRAINSTORM CELL THERAPEUTICS INC.
- filed_at: 2024-04-17T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1137883/000110465924047974/0001104659-24-047974-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1137883/000110465924047974/tm2412023d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-047974
- JSON: https://secwatch.observer/filing/0001104659-24-047974.json
- Plain text: https://secwatch.observer/filing/0001104659-24-047974.txt

## Key facts
- Executive change
  Stacy Lindborg was appointed as member of the Board at BRAINSTORM CELL THERAPEUTICS INC..
  - Action: appointed
  - Role: member of the Board
  source text: Dr. Lindborg has been appointed to serve as a member of the Board, with effect from the Separation Date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1137883/000110465924047974/0001104659-24-047974-index.htm
- Executive change
  Stacy Lindborg resigned as Co-Chief Executive Officer at BRAINSTORM CELL THERAPEUTICS INC..
  - Action: resigned
  - Role: Co-Chief Executive Officer
  source text: Dr. Stacy Lindborg, the Co-Chief Executive Officer of Brainstorm Cell Therapeutics Inc. (the “Company”), provided the Company with notice of her intent to resign from her current role at the Company, effective as of May 9, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1137883/000110465924047974/0001104659-24-047974-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.